Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at http://www.bretjenseninvests.com. Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.

Recent Articles By The Author

Big-Game Hunting for My Next 10-Bagger

Big-Game Hunting for My Next 10-Bagger

It's every investor's dream to find a stock that goes up at least 1,000%; here are a few that did.

Strategies for 3 Biotechs Before FDA Action

Strategies for 3 Biotechs Before FDA Action

Leading up to potential FDA approvals can be particularly 'dicey' times for biotech investors.

Latest Reasons to Avoid Alzheimer's Plays

Latest Reasons to Avoid Alzheimer's Plays

Eli Lilly, AstraZeneca and vTv Therapeutics show why it's best to stay away from biotech's black hole.

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector

I continue to see these names as bargains in the biotech and biopharma space.

Insiders Are Buying These 2 Stocks Now

Insiders Are Buying These 2 Stocks Now

Here are a couple of names that have piqued my curiosity over the past few weeks.

Small Cap Biotech Bargains

Small Cap Biotech Bargains

Here are 2 small caps I continue to see as bargains in this space.

ASCO's Big Winner: Loxo Oncology

ASCO's Big Winner: Loxo Oncology

Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.

How to Manage Risk in Biotech Stocks

How to Manage Risk in Biotech Stocks

T2 Biosystems' recent run-up on a positive event provides an important lesson for biotech investors.

Two Antibiotic Plays

Two Antibiotic Plays

They may not get all the attention, but antibiotic drugs are increasingly important.

How to Manage Risk in Biotech

How to Manage Risk in Biotech

T2 Biosystems used the run-up on a positive event - an FDA approval - to raise additional capital.